Physiological doses of progesterone potentiate the effects of triazolam in healthy, premenopausal women
- 109 Downloads
Gender plays a critical role in the effects of drugs and drug abuse liability. Biological factors, including ovarian hormones, may contribute to gender differences in drug abuse. Preclinical and some clinical research suggests that progesterone and its metabolites have activity at the GABAA receptor and may enhance the effect of GABAergic compounds (e.g., benzodiazepines). Because women are exposed to varying levels of progesterone from puberty until menopause, and appear more sensitive to the negative consequences of benzodiazepine use, it is important to understand the impact of progesterone on GABAergic drug effects.
The purpose of this experiment was to characterize the behavioral effects of progesterone, alone and in combination with the short-acting benzodiazepine, triazolam, to determine if progesterone potentiates the behavioral effects of triazolam.
Oral micronized progesterone (0, 100, and 200 mg) and oral triazolam (0.00, 0.12, and 0.25 mg/70 kg) were administered to healthy, premenopausal women (n = 11) under conditions of low circulating sex hormones. The subjective, performance and physiological effects of progesterone, alone and in combination with triazolam, were assessed.
Triazolam alone produced prototypical sedative-like effects. Progesterone alone also engendered some sedative effects, although the time course of the effects was more limited than that of triazolam. Progesterone increased and extended the duration of triazolam effects and delayed the onset of triazolam peak effects, most notably at the 0.12 mg/70 kg dose.
Progesterone potentiates the behavioral effects of benzodiazepines and may contribute to benzodiazepine use and abuse among women.
KeywordsProgesterone Prometrium Neurosteroid Benzodiazepine Triazolam Subjective effects Performance effects Women’s health
The authors wish to thank Stephanie LaBedz, Stephanie Douglas, Dustin Lee, Laura Mudd, Caroline Kimathi, Cleeve Emurian, Glenn Robbins, Phoebe Brown, and Beth Eaves for expert technical assistance. We also thank Steven Sitzlar of the University of Kentucky Investigational Drug Service.
This research and the preparation of this manuscript were supported by grants from the National Institute on Drug Abuse (R36 DA024127, T32 DA007304) and the Center for Biomedical Research Excellence (P20 RR015592). The authors do not have any financial relationship with these funding sources and have no conflict of interest to report.
- Kandel DB, Warner LA, Kessler RC (1998) The epidemiology of substance use and dependence among women. In: Wetherington CL, Roman AB (eds) Drug addiction research and the health of women. Diane, Darby, pp 105–130Google Scholar
- Paul SM, Purdy RH (1992) Neuroactive steroids. FASEB 6(6):2311–2322Google Scholar
- Simoni-Wastila L, Ross-Degnan D, Mah C, Gao X, Brown J, Cosler LE, Fanning T, Gallagher P, Salzman C, Soumerai SB (2004) A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders. Clin Ther 26(2):322–336PubMedCrossRefGoogle Scholar
- Substance Abuse and Mental Health Services Administration (2009) Results from the 2008 National Survey on Drug Use and Health: national findings. Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434, Rockville, MDGoogle Scholar
- World Medical Association Declaration of Helsinki Ethical Principle for Medical Research Involving Human Subjects. Last revised October 2008. Available at http://www.wma.net/en/30publications/10policies/b3/index.html